Definitive Diagnostics, Inc.

Definitive Diagnostics' mission is to improve cancer survival rates and quality of life for cancer patients through accurate, earlier diagnosis, and eliminate wasteful downline testing. Our patented platform identifies, with high precision, some of the most prevalent (breast, lung, colorectal) and aggressive (pancreatic, ovarian) cancers, and many cancer subtypes. Definitive Diagnostics' patented technology relies on abundant cancer-related proteins found in blood that signal, through a series of proprietary biomarker patterns, the presence of cancer across all stages. Independent audits support 97%-99% sensitivity and specificity across cancer types, with equivalent success rates at Stage 1. 98% accuracy in determining TOO, i.e., specific cancer type (when one is present) with overall minimal false positive/negative rates (1-3%). Definitive Diagnostics is currently completing development of a series of AI-enhanced diagnostic screening tests, automated for global scalability, and independently validated.